Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis. Issue 2 (30th April 2014) - Prosperini, Luca; De Angelis, Floriana; De Angelis, Rosanna; Fanelli, Fulvia; Pozzilli, Carlo